The innate and adaptive immunostimulatory potential of synthetic STING activation has greatly incentivized the discovery and characterization of novel molecular entities that stimulate this pathway for anti-cancer therapies (45, 52) and as a strategy to enhance vaccination (53, 54). The gene discussed is STING1; the disease is cancer.